Article Text

Download PDFPDF
Tobacco legislation reform and industry response in Israel

Statistics from Altmetric.com

Footnotes

  • Twitter @yaelbarzeev

  • Contributors HL, CJB, LA and YB-Z conceived the idea for the manuscript. YB-Z, SK, HHG, EG and HL collected the data. YB-Z wrote the manuscript with all other authors contributing. All authors reviewed and authorised the final version submitted.

  • Funding This research was supported by the National Cancer Institute (R01CA239178-01A1; MPIs: CJB, HL). Dr Berg is also supported by the National Cancer Institute (R01CA215155-01A1; PI: CJB; R01CA179422-01; PI: CJB), the US Fogarty International Center/National Cancer Institute (1R01TW010664-01; MPIs: CJB, Kegler), and Fogarty/NIEHS (D43ES030927-01; MPIs: CJB, Marsit, Sturua).

  • Competing interests YB-Z has received fees for lectures from Pfizer Israel Ltd, Novartis NCH and GSK Consumer Health (distributors of smoking cessation pharmacotherapy in Israel) in the past (2012-07/2019). HL had received fees for lectures from Pfizer Israel Ltd (distributor of a smoking cessation pharmacotherapy in Israel) in 2017. LA receives royalties for the sale of Text2Quit and is a shareholder in Welltok, Inc.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.